Mesenchymal stem cell transplantation as a new treatment strategy in patents with multiple sclerosis and amyotrophic lateral sclerosis: a five year experience

Cellular Therapy and Transplantation

Miroslav M. Odinak¹  Dmitriy G. Polyntsev¹  Vadim V. Tyrenko¹  Alexander B. Smolyaninov¹  Gennadiy N. Bisaga¹  Andrey V. Novitsky¹  Petr V. Krugliakov¹ 

关键词: stem cell;    cell therapy;    multiple sclerosis;    lateral sclerosis;    transplantation;    mesenchymal stem cells;   

DOI  :  10.3205/ctt-2010-No9-abstract52

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

Background:Themostsignificantdegenerativeandprogressivediseasesareamyotrophiclateralsclerosis(ALS)andmultiplesclerosis(MS).Stemcelltransplantationhasbeenproposedasthemostpromisingtherapeuticstrategyforthiscategoryofpatients.Humanmesenchymalstemcells(MSCs)aremultipotentcellsthathavethepotentialtodifferentiateintolineagesofmesenchymaltissuesincludingbone,muscle,neurons,andoligodendrocytes.Materialsandmethods:From2005to2010autologousMSCswereisolatedfromthebonemarrowof8patientswithMS(3F,5M,aged25–39yrs,duration3–14ys,EDSS3.0–7.0)and12patientswithALS(5F,7M,aged38–63yrs,duration15–57months,32–20pointsontheALSSSscale)Growthkinetics,immunophenotypes,andkaryotypeswereevaluatedduringinvitroexpansion.TheinvitroexpandedMSCsdidnotshowanybacterialorfungalcontamination,hemopoieticcellpresence,chromosomalalterations,orearlycellularsenescence.ThepatientsreceivedmonthlyintravenousinjectionsofautologousMSCsindosesof2x106cells/kgfor3–20months.Nosignsofabnormalcellproliferationwereobserved.Results:Nosignificantacuteorlatesideeffectswereinevidence.MinoradverseeventswereheadachesandtransienthyperthermiaaftertheMSCinfusion.FourALSpatientsdied3–6mthsafterthestartoftherapyduetoconditionsnotdirectlyrelatedtotheMSCtherapyitself:1ptcommittedsuicide(hadnothadanypositiveresultsfromtherapy),2ptsdiedofcardiacarrest(bothhadalonghistoryofischemiccardiacdisease),and1ptdiedofdiseaseprogressionandrefusalofmechanicalventilation.ThreeALSpatientsshowasignificant(for4–10mo),3adoubtful(for1–3mo),and5alackofslowingofprogression.TheEDSSscoresof7MSpatientsshowastabilizationanddecreasein0.5to1pointdespiterepeatedrelapsesevery3moin1pt,andonepatientexperienceddiseaseprogression.Conclusion:Afive-yearexperienceofthestemcelltherapyinMSandALSdemonstratesthatMSCtherapyissafeandrepresentsagoodchanceforMSpatients,butisconsiderablylesspreferableinALSpatientsandmaybeusedasapalliativetreatment.

【 授权许可】

Unknown